Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9 Ha'ta'asiya St RA'ANANA 4365007 |
Tel: | 1-609-4603588 |
Website: | https://www.urogen.com |
IR: | See website |
Key People | ||
Elizabeth A. Barrett President, Chief Executive Officer, Director | Dong Kim Chief Financial Officer | Jason Drew Smith Chief Compliance Officer, General Counsel, Corporate Secretary | Mark P. Schoenberg Chief Medical Officer |
Business Overview |
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). |
Financial Overview |
For the fiscal year ended 31 December 2023, Urogen Pharma Ltd revenues increased 29% to $82.7M. Net loss decreased 7% to $102.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development Expenses, Net decrease of 13% to $43.7M (expense), INTEREST AND OTHER (INCOME) EXPENSES, NE increase from $938K to $2.6M (income). |
Employees: | 198 as of Jan 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $457.38M as of Dec 31, 2023 |
Annual revenue (TTM): | $82.71M as of Dec 31, 2023 |
EBITDA (TTM): | -$64.71M as of Dec 31, 2023 |
Net annual income (TTM): | -$102.24M as of Dec 31, 2023 |
Free cash flow (TTM): | -$76.57M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 34,122,087 as of Mar 7, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |